Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Other Accumulated Expenses (2016 - 2025)

Historic Other Accumulated Expenses for Coherus Oncology (CHRS) over the last 13 years, with Q3 2025 value amounting to $7.1 million.

  • Coherus Oncology's Other Accumulated Expenses fell 5110.15% to $7.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.1 million, marking a year-over-year decrease of 5110.15%. This contributed to the annual value of $20.0 million for FY2024, which is 16255.9% up from last year.
  • Latest data reveals that Coherus Oncology reported Other Accumulated Expenses of $7.1 million as of Q3 2025, which was down 5110.15% from $6.8 million recorded in Q2 2025.
  • Coherus Oncology's 5-year Other Accumulated Expenses high stood at $20.0 million for Q4 2024, and its period low was $3.5 million during Q4 2021.
  • In the last 5 years, Coherus Oncology's Other Accumulated Expenses had a median value of $10.9 million in 2021 and averaged $11.2 million.
  • In the last 5 years, Coherus Oncology's Other Accumulated Expenses tumbled by 7133.48% in 2021 and then surged by 20452.46% in 2022.
  • Coherus Oncology's Other Accumulated Expenses (Quarter) stood at $3.5 million in 2021, then surged by 204.52% to $10.6 million in 2022, then fell by 28.27% to $7.6 million in 2023, then surged by 162.56% to $20.0 million in 2024, then tumbled by 64.53% to $7.1 million in 2025.
  • Its last three reported values are $7.1 million in Q3 2025, $6.8 million for Q2 2025, and $11.4 million during Q1 2025.